Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Paying user area
Try for free
Medtronic PLC pages available for free this week:
- Statement of Comprehensive Income
- Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Long-term (Investment) Activity Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Capital Asset Pricing Model (CAPM)
- Dividend Discount Model (DDM)
- Net Profit Margin since 2005
- Price to Sales (P/S) since 2005
- Analysis of Revenues
- Analysis of Debt
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Medtronic PLC for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Short-term Activity Ratios (Summary)
Based on: 10-Q (reporting date: 2026-01-23), 10-Q (reporting date: 2025-10-24), 10-Q (reporting date: 2025-07-25), 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30), 10-K (reporting date: 2021-04-30), 10-Q (reporting date: 2021-01-29), 10-Q (reporting date: 2020-10-30), 10-Q (reporting date: 2020-07-31).
An analysis of short-term operating activity ratios reveals several trends over the observed period. Inventory turnover generally remained stable between 2.10 and 2.47 for the majority of the period, before declining to a low of 1.92 and subsequently fluctuating between 1.92 and 2.15. Receivables turnover exhibited a similar pattern of relative stability, averaging around 5.5, with a slight downward trend in the latter half of the period. Payables turnover demonstrated a more pronounced decline, starting at 5.56 and decreasing to a low of 4.03, with some recovery in later periods, but remaining below initial levels. Working capital turnover showed considerable fluctuation, increasing from 2.44 to 3.84 before returning to levels around 2.4 to 3.2.
- Inventory Management
- The average inventory processing period generally increased over the period, rising from 174 days to 185 days, indicating a lengthening time to convert inventory into sales. This increase coincides with the observed decline in inventory turnover, suggesting potential challenges in inventory management efficiency.
- Receivables Management
- The average receivable collection period remained relatively consistent, fluctuating between 63 and 70 days. While generally stable, a slight increase is observed towards the end of the period, potentially indicating a slower collection of receivables. This aligns with the slight decrease in receivables turnover.
- Payables Management
- The average payables payment period increased significantly from 66 days to 91 days before decreasing to 75 days. This suggests a lengthening of the time taken to settle obligations to suppliers, potentially reflecting a strategy to preserve cash or negotiate extended payment terms. The decline in payables turnover supports this observation.
- Operating and Cash Cycles
- The operating cycle initially decreased, reaching a low of 211 days, before increasing to 260 days, and then decreasing again. The cash conversion cycle followed a similar pattern, initially decreasing to 143 days, then increasing to 189 days, and subsequently decreasing. These cycles are influenced by changes in all three components – inventory, receivables, and payables – and reflect the overall efficiency of the company’s working capital management. The increase in both cycles suggests a potential slowdown in the conversion of investments in working capital into cash.
Overall, the observed trends suggest a potential shift in working capital management practices. While receivables management remained relatively stable, inventory and payables management experienced notable changes, impacting the operating and cash conversion cycles. The fluctuations in working capital turnover indicate a dynamic environment requiring ongoing monitoring and potential adjustments to optimize efficiency.
Turnover Ratios
Average No. Days
Inventory Turnover
| Jan 23, 2026 | Oct 24, 2025 | Jul 25, 2025 | Apr 25, 2025 | Jan 24, 2025 | Oct 25, 2024 | Jul 26, 2024 | Apr 26, 2024 | Jan 26, 2024 | Oct 27, 2023 | Jul 28, 2023 | Apr 28, 2023 | Jan 27, 2023 | Oct 28, 2022 | Jul 29, 2022 | Apr 29, 2022 | Jan 28, 2022 | Oct 29, 2021 | Jul 30, 2021 | Apr 30, 2021 | Jan 29, 2021 | Oct 30, 2020 | Jul 31, 2020 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||
| Cost of products sold, excluding amortization of intangible assets | ||||||||||||||||||||||||||||||
| Inventories | ||||||||||||||||||||||||||||||
| Short-term Activity Ratio | ||||||||||||||||||||||||||||||
| Inventory turnover1 | ||||||||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| Inventory Turnover, Competitors2 | ||||||||||||||||||||||||||||||
| Abbott Laboratories | ||||||||||||||||||||||||||||||
| Intuitive Surgical Inc. | ||||||||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-01-23), 10-Q (reporting date: 2025-10-24), 10-Q (reporting date: 2025-07-25), 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30), 10-K (reporting date: 2021-04-30), 10-Q (reporting date: 2021-01-29), 10-Q (reporting date: 2020-10-30), 10-Q (reporting date: 2020-07-31).
1 Q3 2026 Calculation
Inventory turnover
= (Cost of products sold, excluding amortization of intangible assetsQ3 2026
+ Cost of products sold, excluding amortization of intangible assetsQ2 2026
+ Cost of products sold, excluding amortization of intangible assetsQ1 2026
+ Cost of products sold, excluding amortization of intangible assetsQ4 2025)
÷ Inventories
= ( + + + )
÷ =
2 Click competitor name to see calculations.
Inventory turnover exhibited a generally stable pattern over the observed period, with fluctuations occurring within a relatively narrow range. Initial values indicated a turnover of 2.10, increasing to 2.47 over the first six quarters before experiencing a gradual decline. The most recent periods show a slight stabilization, though remain below the peak observed in 2021.
- Overall Trend
- The inventory turnover ratio demonstrated a slight upward trend from July 2020 to July 2021, increasing from 2.10 to 2.47. Following this peak, the ratio generally decreased, reaching a low of 1.92 in January 2023. A modest recovery was then observed, with the ratio fluctuating between 1.91 and 2.15 over the subsequent six quarters. The latest reported value, in January 2026, is 1.98.
- Short-Term Fluctuations
- Several short-term fluctuations are apparent. A notable increase occurred between January 2021 (2.24) and July 2021 (2.47). Conversely, a decline was observed between October 2022 (2.00) and January 2023 (1.92). The period from April 2024 to October 2024 showed relative stability, with the ratio remaining around 2.1. The most recent quarter shows a slight decrease.
- Recent Performance
- In the most recent four quarters, the inventory turnover ratio has remained relatively consistent, fluctuating between 2.02 and 2.15. This suggests a stabilization of inventory management practices or demand patterns. However, the current level is still below the peak turnover achieved in mid-2021.
- Inventory and Cost of Goods Sold Relationship
- The cost of products sold generally increased over the period, with some quarterly variations. Simultaneously, inventory levels also increased, particularly from October 2021 onwards. The combination of these factors contributed to the observed fluctuations in the inventory turnover ratio. The increase in inventory, coupled with a relatively stable cost of goods sold, likely contributed to the downward pressure on the turnover ratio after July 2021.
The observed trends suggest a dynamic relationship between inventory levels, cost of goods sold, and the efficiency of inventory management. Continued monitoring of these metrics is recommended to identify any significant shifts in operational performance.
Receivables Turnover
| Jan 23, 2026 | Oct 24, 2025 | Jul 25, 2025 | Apr 25, 2025 | Jan 24, 2025 | Oct 25, 2024 | Jul 26, 2024 | Apr 26, 2024 | Jan 26, 2024 | Oct 27, 2023 | Jul 28, 2023 | Apr 28, 2023 | Jan 27, 2023 | Oct 28, 2022 | Jul 29, 2022 | Apr 29, 2022 | Jan 28, 2022 | Oct 29, 2021 | Jul 30, 2021 | Apr 30, 2021 | Jan 29, 2021 | Oct 30, 2020 | Jul 31, 2020 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||
| Net sales | ||||||||||||||||||||||||||||||
| Accounts receivable, less allowances and credit losses | ||||||||||||||||||||||||||||||
| Short-term Activity Ratio | ||||||||||||||||||||||||||||||
| Receivables turnover1 | ||||||||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| Receivables Turnover, Competitors2 | ||||||||||||||||||||||||||||||
| Abbott Laboratories | ||||||||||||||||||||||||||||||
| Elevance Health Inc. | ||||||||||||||||||||||||||||||
| Intuitive Surgical Inc. | ||||||||||||||||||||||||||||||
| UnitedHealth Group Inc. | ||||||||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-01-23), 10-Q (reporting date: 2025-10-24), 10-Q (reporting date: 2025-07-25), 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30), 10-K (reporting date: 2021-04-30), 10-Q (reporting date: 2021-01-29), 10-Q (reporting date: 2020-10-30), 10-Q (reporting date: 2020-07-31).
1 Q3 2026 Calculation
Receivables turnover
= (Net salesQ3 2026
+ Net salesQ2 2026
+ Net salesQ1 2026
+ Net salesQ4 2025)
÷ Accounts receivable, less allowances and credit losses
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The receivables turnover ratio for the analyzed period demonstrates a generally stable pattern with moderate fluctuations. Initially, the ratio decreased from 5.73 in July 2020 to 5.21 in October 2020, before exhibiting a slight recovery to 5.35 in January 2021. Subsequent quarters showed incremental increases, peaking at 5.82 in July 2021, followed by a slight decline to 5.79 in October 2021.
A relatively consistent range was maintained through January 2022 (5.84) and April 2022 (5.71). A more noticeable decrease occurred in July 2022, falling to 5.85, and continued into October 2022 (5.48) and January 2023 (5.23). The ratio remained subdued through April 2023 (5.21) before showing some improvement, reaching 5.44 in July 2023.
The latter portion of the analyzed period reveals a slight downward trend, with the ratio fluctuating between 5.27 and 5.58 from October 2023 through January 2026. While there are minor variations, the ratio generally remains within a narrow band, suggesting consistent efficiency in collecting receivables.
- Overall Trend
- The receivables turnover ratio exhibits a generally stable trend over the analyzed period, fluctuating between approximately 5.15 and 5.85. There isn't a strong, sustained upward or downward trajectory, indicating relatively consistent collection practices.
- Notable Fluctuations
- The most significant declines in the ratio occurred between October 2020 and January 2021, and again between July 2022 and January 2023. These periods warrant further investigation to determine the underlying causes, such as changes in credit terms, customer payment behavior, or sales composition.
- Recent Performance
- In the most recent quarters, the ratio has remained relatively stable, hovering around 5.4 to 5.6. This suggests that the company has maintained a consistent level of efficiency in converting receivables into cash, despite fluctuations in net sales.
- Potential Implications
- A consistent receivables turnover ratio generally indicates effective credit and collection policies. However, the slight downward trend in the most recent periods could suggest a potential need to review these policies to ensure continued efficiency. Further analysis, considering industry benchmarks, is recommended.
Payables Turnover
| Jan 23, 2026 | Oct 24, 2025 | Jul 25, 2025 | Apr 25, 2025 | Jan 24, 2025 | Oct 25, 2024 | Jul 26, 2024 | Apr 26, 2024 | Jan 26, 2024 | Oct 27, 2023 | Jul 28, 2023 | Apr 28, 2023 | Jan 27, 2023 | Oct 28, 2022 | Jul 29, 2022 | Apr 29, 2022 | Jan 28, 2022 | Oct 29, 2021 | Jul 30, 2021 | Apr 30, 2021 | Jan 29, 2021 | Oct 30, 2020 | Jul 31, 2020 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||
| Cost of products sold, excluding amortization of intangible assets | ||||||||||||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||||||||||||
| Short-term Activity Ratio | ||||||||||||||||||||||||||||||
| Payables turnover1 | ||||||||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| Payables Turnover, Competitors2 | ||||||||||||||||||||||||||||||
| Abbott Laboratories | ||||||||||||||||||||||||||||||
| Elevance Health Inc. | ||||||||||||||||||||||||||||||
| Intuitive Surgical Inc. | ||||||||||||||||||||||||||||||
| UnitedHealth Group Inc. | ||||||||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-01-23), 10-Q (reporting date: 2025-10-24), 10-Q (reporting date: 2025-07-25), 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30), 10-K (reporting date: 2021-04-30), 10-Q (reporting date: 2021-01-29), 10-Q (reporting date: 2020-10-30), 10-Q (reporting date: 2020-07-31).
1 Q3 2026 Calculation
Payables turnover
= (Cost of products sold, excluding amortization of intangible assetsQ3 2026
+ Cost of products sold, excluding amortization of intangible assetsQ2 2026
+ Cost of products sold, excluding amortization of intangible assetsQ1 2026
+ Cost of products sold, excluding amortization of intangible assetsQ4 2025)
÷ Accounts payable
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The accounts payable turnover ratio for the observed period exhibits fluctuations, generally trending downwards before stabilizing and showing a slight increase in the most recent quarters. Initial values indicate a relatively healthy rate of paying suppliers, which subsequently experiences periods of decline and recovery.
- Overall Trend
- From July 2020 through April 2023, a general downward trend in the payables turnover ratio is apparent. The ratio decreased from 5.56 to a low of 4.03. Following this decline, the ratio demonstrates a period of relative stability and modest improvement, increasing to 4.85 by October 2025.
- Initial Period (July 2020 – October 2021)
- The ratio begins at 5.56 and fluctuates between 5.19 and 5.67 over the first five quarters. This suggests a consistent, relatively efficient management of accounts payable during this timeframe. The values remain above 5.0, indicating that the company paid its suppliers more than five times per year on average.
- Period of Decline (January 2022 – April 2023)
- A noticeable decline is observed from January 2022, with the ratio decreasing from 5.14 to 4.03 in April 2023. This suggests a lengthening of the time taken to settle obligations with suppliers. This could be due to a variety of factors, including strategic decisions to preserve cash, or potentially, emerging issues with supplier relationships or payment processing.
- Stabilization and Recovery (July 2023 – October 2025)
- Beginning in July 2023, the ratio begins to recover, reaching 5.09 by October 2023. This upward momentum continues, albeit modestly, with the ratio stabilizing around 4.75 to 4.85 in the final quarters observed. This suggests a return to more efficient accounts payable management, although not reaching the levels seen in the initial period.
- Relationship to Cost of Goods Sold
- While the payables turnover ratio fluctuates, the cost of products sold generally increases over the period. This suggests that the company’s purchasing activity is growing, but the efficiency with which it manages its payables is not consistently keeping pace with that growth. The decline in the ratio during the period of January 2022 to April 2023 coincides with a period of increasing cost of goods sold, potentially exacerbating the impact on the turnover ratio.
Working Capital Turnover
| Jan 23, 2026 | Oct 24, 2025 | Jul 25, 2025 | Apr 25, 2025 | Jan 24, 2025 | Oct 25, 2024 | Jul 26, 2024 | Apr 26, 2024 | Jan 26, 2024 | Oct 27, 2023 | Jul 28, 2023 | Apr 28, 2023 | Jan 27, 2023 | Oct 28, 2022 | Jul 29, 2022 | Apr 29, 2022 | Jan 28, 2022 | Oct 29, 2021 | Jul 30, 2021 | Apr 30, 2021 | Jan 29, 2021 | Oct 30, 2020 | Jul 31, 2020 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||
| Current assets | ||||||||||||||||||||||||||||||
| Less: Current liabilities | ||||||||||||||||||||||||||||||
| Working capital | ||||||||||||||||||||||||||||||
| Net sales | ||||||||||||||||||||||||||||||
| Short-term Activity Ratio | ||||||||||||||||||||||||||||||
| Working capital turnover1 | ||||||||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| Working Capital Turnover, Competitors2 | ||||||||||||||||||||||||||||||
| Abbott Laboratories | ||||||||||||||||||||||||||||||
| Elevance Health Inc. | ||||||||||||||||||||||||||||||
| Intuitive Surgical Inc. | ||||||||||||||||||||||||||||||
| UnitedHealth Group Inc. | ||||||||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-01-23), 10-Q (reporting date: 2025-10-24), 10-Q (reporting date: 2025-07-25), 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30), 10-K (reporting date: 2021-04-30), 10-Q (reporting date: 2021-01-29), 10-Q (reporting date: 2020-10-30), 10-Q (reporting date: 2020-07-31).
1 Q3 2026 Calculation
Working capital turnover
= (Net salesQ3 2026
+ Net salesQ2 2026
+ Net salesQ1 2026
+ Net salesQ4 2025)
÷ Working capital
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The working capital turnover ratio for the observed period demonstrates considerable fluctuation. Initially, the ratio exhibited a decline from 2.44 in July 2020 to 2.00 in October 2020, followed by relative stability around the 2.0 to 2.2 range through January 2022. A significant increase is then observed, peaking at 3.84 in January 2022, before decreasing to 2.82 in October 2022.
Subsequent quarters show continued variability. The ratio generally trended upward from 2.81 in January 2023 to 3.22 in October 2024, with intermittent dips. The most recent periods, from January 2025 through July 2025, show a decline, falling to 2.92 in July 2025. A subsequent increase is observed in October 2025, followed by a slight decrease in January 2026.
- Overall Trend
- While fluctuations are prominent, a general upward trend in working capital turnover is discernible over the entire period, particularly from early 2022 through late 2024. However, the most recent quarters suggest a potential stabilization or slight downward correction.
- Peak and Trough
- The highest recorded ratio was 3.84 in January 2022, indicating efficient utilization of working capital during that period. The lowest ratio was 2.00 in October 2020, suggesting a less efficient use of working capital at that time.
- Relationship to Net Sales
- The observed fluctuations in the working capital turnover ratio appear to correlate with changes in net sales. The peak in turnover in January 2022 coincided with relatively stable net sales, while the initial decline in 2020 occurred alongside a decrease in net sales. The increases observed in late 2023 and 2024 align with increases in net sales.
- Recent Performance
- The ratio has decreased from a high of 3.22 in October 2024 to 2.43 in January 2026. This recent decline warrants further investigation to determine if it represents a temporary fluctuation or a more sustained shift in operational efficiency.
In conclusion, the working capital turnover ratio demonstrates a dynamic pattern over the analyzed timeframe. While generally trending upward, the ratio is subject to considerable quarterly variation, influenced by fluctuations in both working capital and net sales. Recent performance suggests a potential shift towards lower turnover, requiring continued monitoring.
Average Inventory Processing Period
| Jan 23, 2026 | Oct 24, 2025 | Jul 25, 2025 | Apr 25, 2025 | Jan 24, 2025 | Oct 25, 2024 | Jul 26, 2024 | Apr 26, 2024 | Jan 26, 2024 | Oct 27, 2023 | Jul 28, 2023 | Apr 28, 2023 | Jan 27, 2023 | Oct 28, 2022 | Jul 29, 2022 | Apr 29, 2022 | Jan 28, 2022 | Oct 29, 2021 | Jul 30, 2021 | Apr 30, 2021 | Jan 29, 2021 | Oct 30, 2020 | Jul 31, 2020 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||||||||||||||||||||||||||
| Inventory turnover | ||||||||||||||||||||||||||||||
| Short-term Activity Ratio (no. days) | ||||||||||||||||||||||||||||||
| Average inventory processing period1 | ||||||||||||||||||||||||||||||
| Benchmarks (no. days) | ||||||||||||||||||||||||||||||
| Average Inventory Processing Period, Competitors2 | ||||||||||||||||||||||||||||||
| Abbott Laboratories | ||||||||||||||||||||||||||||||
| Intuitive Surgical Inc. | ||||||||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-01-23), 10-Q (reporting date: 2025-10-24), 10-Q (reporting date: 2025-07-25), 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30), 10-K (reporting date: 2021-04-30), 10-Q (reporting date: 2021-01-29), 10-Q (reporting date: 2020-10-30), 10-Q (reporting date: 2020-07-31).
1 Q3 2026 Calculation
Average inventory processing period = 365 ÷ Inventory turnover
= 365 ÷ =
2 Click competitor name to see calculations.
The average inventory processing period exhibited fluctuations over the observed timeframe. Initially, a decreasing trend was apparent, followed by a period of relative stability and then an increase, concluding with a slight decline in the most recent periods.
- Overall Trend
- The average inventory processing period began at 174 days in July 2020 and generally decreased to a low of 148 days by July 2021. Following this, the period increased, peaking at 191 days in July 2022, before decreasing to 185 days by January 2026. This suggests an initial improvement in inventory management efficiency, followed by a lengthening of the processing cycle, and a recent slight recovery.
- Short-Term Fluctuations
- From October 2020 through July 2021, the average inventory processing period demonstrated consistent declines, indicating improved efficiency in converting inventory into sales. A subsequent increase was observed from July 2021 to October 2022, suggesting potential challenges in inventory management during that period. The period remained elevated through April 2023, before showing a modest decrease.
- Recent Performance
- The most recent observations, from October 2024 to January 2026, show a relatively stable period, fluctuating between 178 and 187 days. This suggests a potential stabilization of inventory processing times, although remaining above the lows observed in 2021.
- Correlation with Inventory Turnover
- The observed trends in the average inventory processing period are inversely related to the inventory turnover ratio. As the inventory turnover ratio decreased from 2.47 in July 2021 to 1.95 in January 2023, the average inventory processing period increased. This relationship reinforces the understanding that a lower turnover rate corresponds to a longer time to process inventory.
In summary, the company experienced a period of improving inventory efficiency, followed by a lengthening of the inventory processing cycle, and a recent stabilization. Continued monitoring of these trends is recommended to identify potential areas for improvement in inventory management.
Average Receivable Collection Period
| Jan 23, 2026 | Oct 24, 2025 | Jul 25, 2025 | Apr 25, 2025 | Jan 24, 2025 | Oct 25, 2024 | Jul 26, 2024 | Apr 26, 2024 | Jan 26, 2024 | Oct 27, 2023 | Jul 28, 2023 | Apr 28, 2023 | Jan 27, 2023 | Oct 28, 2022 | Jul 29, 2022 | Apr 29, 2022 | Jan 28, 2022 | Oct 29, 2021 | Jul 30, 2021 | Apr 30, 2021 | Jan 29, 2021 | Oct 30, 2020 | Jul 31, 2020 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||||||||||||||||||||||||||
| Receivables turnover | ||||||||||||||||||||||||||||||
| Short-term Activity Ratio (no. days) | ||||||||||||||||||||||||||||||
| Average receivable collection period1 | ||||||||||||||||||||||||||||||
| Benchmarks (no. days) | ||||||||||||||||||||||||||||||
| Average Receivable Collection Period, Competitors2 | ||||||||||||||||||||||||||||||
| Abbott Laboratories | ||||||||||||||||||||||||||||||
| Elevance Health Inc. | ||||||||||||||||||||||||||||||
| Intuitive Surgical Inc. | ||||||||||||||||||||||||||||||
| UnitedHealth Group Inc. | ||||||||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-01-23), 10-Q (reporting date: 2025-10-24), 10-Q (reporting date: 2025-07-25), 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30), 10-K (reporting date: 2021-04-30), 10-Q (reporting date: 2021-01-29), 10-Q (reporting date: 2020-10-30), 10-Q (reporting date: 2020-07-31).
1 Q3 2026 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ =
2 Click competitor name to see calculations.
The average receivable collection period exhibited relative stability over the analyzed period, ranging primarily between 62 and 71 days. While fluctuations occurred, a clear, sustained trend was not readily apparent. Initial values indicated a slight increase from 64 days in July 2020 to 70 days in October 2020, followed by a partial recovery.
- Overall Trend
- The collection period demonstrated a cyclical pattern. Periods of increase were generally followed by periods of decrease, preventing a definitive upward or downward trend from establishing itself. The period remained largely contained within a seven-day range throughout the observation window.
- Short-Term Fluctuations
- A minor peak in the collection period was observed in October 2020 and again in January 2023, reaching 70 days in both instances. Conversely, the lowest values were recorded in July 2021 and January 2026, both at 63 and 65 days respectively. These fluctuations suggest potential seasonality or temporary impacts from specific business events.
- Recent Performance
- In the most recent quarters analyzed, the collection period has fluctuated between 67 and 71 days. The period ended at 65 days in January 2026, representing a slight decrease from the prior quarter. This recent performance is consistent with the historical range observed.
- Consistency
- Despite the fluctuations, the average collection period remained remarkably consistent. The majority of values fell between 66 and 68 days, indicating a stable credit and collection process. This consistency could be attributed to consistent credit policies and effective collection efforts.
In conclusion, the average receivable collection period has remained relatively stable, with minor cyclical variations. No significant or sustained changes were identified during the analyzed timeframe.
Operating Cycle
| Jan 23, 2026 | Oct 24, 2025 | Jul 25, 2025 | Apr 25, 2025 | Jan 24, 2025 | Oct 25, 2024 | Jul 26, 2024 | Apr 26, 2024 | Jan 26, 2024 | Oct 27, 2023 | Jul 28, 2023 | Apr 28, 2023 | Jan 27, 2023 | Oct 28, 2022 | Jul 29, 2022 | Apr 29, 2022 | Jan 28, 2022 | Oct 29, 2021 | Jul 30, 2021 | Apr 30, 2021 | Jan 29, 2021 | Oct 30, 2020 | Jul 31, 2020 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||||||||||||||||||||||||||
| Average inventory processing period | ||||||||||||||||||||||||||||||
| Average receivable collection period | ||||||||||||||||||||||||||||||
| Short-term Activity Ratio | ||||||||||||||||||||||||||||||
| Operating cycle1 | ||||||||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| Operating Cycle, Competitors2 | ||||||||||||||||||||||||||||||
| Abbott Laboratories | ||||||||||||||||||||||||||||||
| Intuitive Surgical Inc. | ||||||||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-01-23), 10-Q (reporting date: 2025-10-24), 10-Q (reporting date: 2025-07-25), 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30), 10-K (reporting date: 2021-04-30), 10-Q (reporting date: 2021-01-29), 10-Q (reporting date: 2020-10-30), 10-Q (reporting date: 2020-07-31).
1 Q3 2026 Calculation
Operating cycle = Average inventory processing period + Average receivable collection period
= + =
2 Click competitor name to see calculations.
The operating cycle, along with its component parts – average inventory processing period and average receivable collection period – exhibits discernible trends over the observed timeframe. Generally, the operating cycle lengthened over the period, though with fluctuations. A closer examination of the individual components reveals the drivers behind this overall trend.
- Average Inventory Processing Period
- The average inventory processing period demonstrated a generally increasing trend. Starting at 174 days in July 2020, it decreased to a low of 148 days in July 2021. However, it then began a consistent climb, reaching 191 days in July 2023 before decreasing slightly to 185 days in January 2026. This suggests a potential slowdown in inventory turnover in recent periods, possibly due to increased inventory levels or slower sales. The period experienced its highest values in the latter portion of the observed timeframe.
- Average Receivable Collection Period
- The average receivable collection period remained relatively stable for much of the period, fluctuating between 63 and 70 days. A slight upward trend is observable, particularly from July 2020 (64 days) to January 2023 (70 days), and again towards the end of the period, reaching 71 days in April 2025. This indicates a potential lengthening in the time taken to collect payments from customers, which could be attributable to changes in credit terms or customer payment behavior.
- Operating Cycle
- The operating cycle initially decreased from 238 days in July 2020 to a low of 211 days in July 2021. Following this, the cycle length increased, peaking at 260 days in January 2023. It then experienced some volatility, but generally remained elevated compared to earlier periods, concluding at 250 days in January 2026. The increase in the operating cycle is largely driven by the lengthening inventory processing period, with the receivable collection period contributing to a lesser extent. The overall trend suggests a longer time required to convert investments in inventory and receivables into cash.
The observed increases in both the inventory processing period and the operating cycle warrant further investigation. Potential causes could include shifts in supply chain dynamics, changes in product mix, or evolving customer payment patterns. Monitoring these trends closely will be crucial for assessing the company’s operational efficiency and liquidity.
Average Payables Payment Period
| Jan 23, 2026 | Oct 24, 2025 | Jul 25, 2025 | Apr 25, 2025 | Jan 24, 2025 | Oct 25, 2024 | Jul 26, 2024 | Apr 26, 2024 | Jan 26, 2024 | Oct 27, 2023 | Jul 28, 2023 | Apr 28, 2023 | Jan 27, 2023 | Oct 28, 2022 | Jul 29, 2022 | Apr 29, 2022 | Jan 28, 2022 | Oct 29, 2021 | Jul 30, 2021 | Apr 30, 2021 | Jan 29, 2021 | Oct 30, 2020 | Jul 31, 2020 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||||||||||||||||||||||||||
| Payables turnover | ||||||||||||||||||||||||||||||
| Short-term Activity Ratio (no. days) | ||||||||||||||||||||||||||||||
| Average payables payment period1 | ||||||||||||||||||||||||||||||
| Benchmarks (no. days) | ||||||||||||||||||||||||||||||
| Average Payables Payment Period, Competitors2 | ||||||||||||||||||||||||||||||
| Abbott Laboratories | ||||||||||||||||||||||||||||||
| Elevance Health Inc. | ||||||||||||||||||||||||||||||
| Intuitive Surgical Inc. | ||||||||||||||||||||||||||||||
| UnitedHealth Group Inc. | ||||||||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-01-23), 10-Q (reporting date: 2025-10-24), 10-Q (reporting date: 2025-07-25), 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30), 10-K (reporting date: 2021-04-30), 10-Q (reporting date: 2021-01-29), 10-Q (reporting date: 2020-10-30), 10-Q (reporting date: 2020-07-31).
1 Q3 2026 Calculation
Average payables payment period = 365 ÷ Payables turnover
= 365 ÷ =
2 Click competitor name to see calculations.
The average payables payment period exhibited fluctuations over the observed period, spanning from July 2020 to July 2025. An initial period of relative stability was followed by increased variability, with a general tendency towards longer payment periods in the latter half of the analyzed timeframe.
- Overall Trend
- The average payables payment period generally increased from 66 days in July 2020 to 75 days in July 2025. However, this increase was not linear, with several periods of decrease interspersed throughout the observation window.
- Initial Period (July 2020 – January 2021)
- The period from July 2020 to January 2021 demonstrated a relatively stable payment period, fluctuating between 66 and 70 days. This suggests consistent supplier payment practices during this timeframe.
- Increase and Peak (April 2021 – January 2022)
- From April 2021, the average payables payment period began to increase, peaking at 82 days in April 2022. This indicates a lengthening of the time taken to settle obligations to suppliers. The increase could be attributable to various factors, such as changes in supplier credit terms, internal cash management strategies, or potential supply chain disruptions.
- Subsequent Fluctuations (February 2022 – July 2025)
- Following the peak in April 2022, the payment period experienced fluctuations, decreasing to 75 days by July 2023, then increasing again to 79 days in January 2025, before settling at 75 days in July 2025. This suggests a dynamic relationship with suppliers and potentially reflects adjustments to payment strategies in response to changing business conditions. The period remained generally above the initial levels observed in 2020 and early 2021.
The observed changes in the average payables payment period warrant further investigation to understand the underlying drivers and their impact on supplier relationships and overall financial health.
Cash Conversion Cycle
| Jan 23, 2026 | Oct 24, 2025 | Jul 25, 2025 | Apr 25, 2025 | Jan 24, 2025 | Oct 25, 2024 | Jul 26, 2024 | Apr 26, 2024 | Jan 26, 2024 | Oct 27, 2023 | Jul 28, 2023 | Apr 28, 2023 | Jan 27, 2023 | Oct 28, 2022 | Jul 29, 2022 | Apr 29, 2022 | Jan 28, 2022 | Oct 29, 2021 | Jul 30, 2021 | Apr 30, 2021 | Jan 29, 2021 | Oct 30, 2020 | Jul 31, 2020 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||||||||||||||||||||||||||
| Average inventory processing period | ||||||||||||||||||||||||||||||
| Average receivable collection period | ||||||||||||||||||||||||||||||
| Average payables payment period | ||||||||||||||||||||||||||||||
| Short-term Activity Ratio | ||||||||||||||||||||||||||||||
| Cash conversion cycle1 | ||||||||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| Cash Conversion Cycle, Competitors2 | ||||||||||||||||||||||||||||||
| Abbott Laboratories | ||||||||||||||||||||||||||||||
| Intuitive Surgical Inc. | ||||||||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-01-23), 10-Q (reporting date: 2025-10-24), 10-Q (reporting date: 2025-07-25), 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30), 10-K (reporting date: 2021-04-30), 10-Q (reporting date: 2021-01-29), 10-Q (reporting date: 2020-10-30), 10-Q (reporting date: 2020-07-31).
1 Q3 2026 Calculation
Cash conversion cycle = Average inventory processing period + Average receivable collection period – Average payables payment period
= + – =
2 Click competitor name to see calculations.
The short-term operating activity of the company, as measured by the cash conversion cycle and its components, exhibits fluctuating trends over the observed period from July 2020 to January 2026. Generally, the cash conversion cycle demonstrates a degree of variability, with periods of relative stability interspersed with noticeable increases.
- Average Inventory Processing Period
- The average time taken to process inventory generally increased over the period. Starting at 174 days in July 2020, it decreased to a low of 148 days in July 2021. However, a consistent upward trend is then observed, peaking at 191 days in July 2023, before decreasing slightly to 185 days in January 2026. This suggests a potential lengthening in the time required to convert raw materials into finished goods and ultimately sell them.
- Average Receivable Collection Period
- The average number of days to collect receivables remained relatively stable for much of the period, fluctuating between 63 and 70 days. A slight increase is observed towards the end of the period, reaching 71 days in April 2025, before decreasing to 65 days in January 2026. This indicates generally consistent efficiency in collecting payments from customers, with a minor potential slowdown in collection timing towards the middle of the observed timeframe.
- Average Payables Payment Period
- The average time taken to pay suppliers showed more significant fluctuations. It began at 66 days in July 2020 and increased to 82 days in April 2022, representing a substantial lengthening of payment terms. Subsequently, it decreased to 65 days in January 2024, before increasing again to 75 days in January 2026. This suggests the company has strategically managed its payment terms to suppliers, potentially leveraging extended payment periods to improve cash flow, but also demonstrating some volatility in this practice.
- Cash Conversion Cycle
- The cash conversion cycle initially decreased from 172 days in July 2020 to 143 days in April 2021. It then experienced a period of increase, peaking at 189 days in January 2024. A decrease is observed in the most recent periods, falling to 175 days in January 2026. The cycle’s movements are largely influenced by the trends in inventory processing and payables payment periods. The increase in the cycle suggests the company is taking longer to convert its investments in inventory and other resources into cash, while the recent decrease indicates some improvement in this efficiency.
Overall, the company’s short-term operating activity demonstrates a dynamic relationship between inventory management, receivables collection, and payables disbursement. The lengthening inventory processing period and fluctuating payables payment period appear to be the primary drivers of changes in the cash conversion cycle.